{"entity":{"type":"insider","cik":"0001266802","url":"/insider/0001266802","json_url":"/insider/0001266802.json","name":"JACOB GARY S","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":11,"first":"2005-03-11","last":"2026-08-07","span_basis":"filed_date"},"name_variants":[{"name":"JACOB GARY S","source":"filing","n_filings":11,"first_seen":"2005-03-11","last_seen":"2026-08-07"}],"transactions":[{"id":9290413,"accession":"0001493152-26-036583","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-26-036583","line_url":"/filing/0001493152-26-036583#line-1","is_derivative":false,"issuer_cik":"0001266802","issuer_name":"OKYO Pharma Ltd","issuer_ticker":"OKYO","issuer_name_source":null,"issuer_url":"/issuer/0001266802","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director, Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"COMMON STOCK","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3500.0,"shares_display":"3,500","price_per_share":1.4,"price_display":"1.40","price_state":"stated","total_value":4900.0,"total_display":"4,900.00","total_whole":"4,900","shares_owned_after":112420.0,"shares_owned_after_display":"112,420","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-21","filed_date":"2026-08-07","scope":"insider"},{"id":6571140,"accession":"0001493152-22-014438","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-014438","line_url":"/filing/0001493152-22-014438#line-1","is_derivative":false,"issuer_cik":"0001266802","issuer_name":"OKYO Pharma Ltd","issuer_ticker":"OKYO","issuer_name_source":null,"issuer_url":"/issuer/0001266802","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"American Depositary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12500.0,"shares_display":"12,500","price_per_share":4.0,"price_display":"4.00","price_state":"stated","total_value":50000.0,"total_display":"50,000.00","total_whole":"50,000","shares_owned_after":12500.0,"shares_owned_after_display":"12,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-19","filed_date":"2022-05-19","scope":"insider"},{"id":5338813,"accession":"0001628280-21-005358","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-21-005358","line_url":"/filing/0001628280-21-005358","is_derivative":false,"issuer_cik":"0001213037","issuer_name":"Cardiff Oncology, Inc.","issuer_ticker":"CRDF","issuer_name_source":null,"issuer_url":"/issuer/0001213037","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2370.0,"shares_display":"2,370","price_per_share":10.417447257383966,"price_display":"10.42","price_state":"stated","total_value":24689.35,"total_display":"24,689.35","total_whole":"24,689","shares_owned_after":21452.0,"shares_owned_after_display":"21,452","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-23","filed_date":"2021-03-23","scope":"insider","n_lines":2},{"id":4149257,"accession":"0001213900-21-010660","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-21-010660","line_url":"/filing/0001213900-21-010660#line-1","is_derivative":false,"issuer_cik":"0001266802","issuer_name":"Virpax Pharmaceuticals, Inc.","issuer_ticker":"VRPX","issuer_name_source":null,"issuer_url":"/issuer/0001266802","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.00001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3500.0,"shares_display":"3,500","price_per_share":6.789,"price_display":"6.79","price_state":"stated","total_value":23761.5,"total_display":"23,761.50","total_whole":"23,762","shares_owned_after":3500.0,"shares_owned_after_display":"3,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-17","filed_date":"2021-02-19","scope":"insider"},{"id":2255952,"accession":"0001104659-20-131213","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-131213","line_url":"/filing/0001104659-20-131213#line-1","is_derivative":false,"issuer_cik":"0001266802","issuer_name":"Hepion Pharmaceuticals, Inc.","issuer_ticker":"HEPA","issuer_name_source":null,"issuer_url":"/issuer/0001266802","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":1.66,"price_display":"1.66","price_state":"stated","total_value":19920.0,"total_display":"19,920.00","total_whole":"19,920","shares_owned_after":12059.0,"shares_owned_after_display":"12,059","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-01","filed_date":"2020-12-01","scope":"insider"},{"id":2173135,"accession":"0001104659-20-063177","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-063177","line_url":"/filing/0001104659-20-063177#line-1","is_derivative":false,"issuer_cik":"0001213037","issuer_name":"Cardiff Oncology, Inc.","issuer_ticker":"CRDF","issuer_name_source":null,"issuer_url":"/issuer/0001213037","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17483.0,"shares_display":"17,483","price_per_share":1.43,"price_display":"1.43","price_state":"stated","total_value":25000.69,"total_display":"25,000.69","total_whole":"25,001","shares_owned_after":19552.0,"shares_owned_after_display":"19,552","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-14","filed_date":"2020-05-18","scope":"insider"},{"id":4363636,"accession":"0001104659-17-035883","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-17-035883","line_url":"/filing/0001104659-17-035883#line-1","is_derivative":false,"issuer_cik":"0001266802","issuer_name":"SYNERGY PHARMACEUTICALS, INC.","issuer_ticker":"SGYP","issuer_name_source":null,"issuer_url":"/issuer/0001266802","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5680.0,"shares_display":"5,680","price_per_share":3.5154,"price_display":"3.52","price_state":"stated","total_value":19967.472,"total_display":"19,967.47","total_whole":"19,967","shares_owned_after":402679.0,"shares_owned_after_display":"402,679","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-26","filed_date":"2017-05-30","scope":"insider"},{"id":7044595,"accession":"0001104659-14-041855","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-14-041855","line_url":"/filing/0001104659-14-041855#line-1","is_derivative":false,"issuer_cik":"0001266802","issuer_name":"SYNERGY PHARMACEUTICALS, INC.","issuer_ticker":"SGYP","issuer_name_source":null,"issuer_url":"/issuer/0001266802","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":4.18,"price_display":"4.18","price_state":"stated","total_value":16720.0,"total_display":"16,720.00","total_whole":"16,720","shares_owned_after":338034.0,"shares_owned_after_display":"338,034","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-27","filed_date":"2014-05-28","scope":"insider"},{"id":4901131,"accession":"0001104659-06-056515","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-06-056515","line_url":"/filing/0001104659-06-056515#line-1","is_derivative":false,"issuer_cik":"0001142380","issuer_name":"CALLISTO PHARMACEUTICALS INC","issuer_ticker":"KAL","issuer_name_source":null,"issuer_url":"/issuer/0001142380","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":0.84,"price_display":"0.84","price_state":"stated","total_value":4200.0,"total_display":"4,200.00","total_whole":"4,200","shares_owned_after":134745.0,"shares_owned_after_display":"134,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-08-21","filed_date":"2006-08-22","scope":"insider"},{"id":1326481,"accession":"0001321543-05-000013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001321543-05-000013","line_url":"/filing/0001321543-05-000013#line-1","is_derivative":false,"issuer_cik":"0001142380","issuer_name":"CALLISTO PHARMACEUTICALS INC","issuer_ticker":"KAL","issuer_name_source":null,"issuer_url":"/issuer/0001142380","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.0,"price_display":"1.00","price_state":"stated","total_value":5000.0,"total_display":"5,000.00","total_whole":"5,000","shares_owned_after":129745.0,"shares_owned_after_display":"129,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-06-16","filed_date":"2005-06-17","scope":"insider"},{"id":1484466,"accession":"0000930413-05-001782","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000930413-05-001782","line_url":"/filing/0000930413-05-001782#line-1","is_derivative":false,"issuer_cik":"0001142380","issuer_name":"CALLISTO PHARMACEUTICALS INC","issuer_ticker":"KAL","issuer_name_source":null,"issuer_url":"/issuer/0001142380","owner_cik":"0001266802","owner_name":"JACOB GARY S","owner_display_name":"JACOB GARY S","owner_url":"/insider/0001266802","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16448.0,"shares_display":"16,448","price_per_share":1.52,"price_display":"1.52","price_state":"stated","total_value":25000.96,"total_display":"25,000.96","total_whole":"25,001","shares_owned_after":124745.0,"shares_owned_after_display":"124,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-03-09","filed_date":"2005-03-11","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":12,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001849296","name":"OKYO Pharma Ltd","url":"/issuer/0001849296","role":"Director, Officer (CHIEF DEVELOPMENT OFFICER)","n_filings":2,"first_seen":"2022-05-19","last_seen":"2026-08-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001213037","name":"Cardiff Oncology, Inc.","url":"/issuer/0001213037","role":"Director","n_filings":2,"first_seen":"2020-05-18","last_seen":"2021-03-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001708331","name":"Virpax Pharmaceuticals, Inc.","url":"/issuer/0001708331","role":"Director","n_filings":1,"first_seen":"2021-02-19","last_seen":"2021-02-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001583771","name":"Hepion Pharmaceuticals, Inc.","url":"/issuer/0001583771","role":"Director","n_filings":1,"first_seen":"2020-12-01","last_seen":"2020-12-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001347613","name":"SYNERGY PHARMACEUTICALS, INC.","url":"/issuer/0001347613","role":"Director, Officer (Chief Executive Officer)","n_filings":2,"first_seen":"2014-05-28","last_seen":"2017-05-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001142380","name":"CALLISTO PHARMACEUTICALS INC","url":"/issuer/0001142380","role":"Director, Officer (Chief Executive Officer)","n_filings":3,"first_seen":"2005-03-11","last_seen":"2006-08-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001266802","retrieved_at":"2026-08-27T07:26:45+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}